Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

60.00
+0.13000.22%
Post-market: 60.000.00000.00%17:20 EDT
Volume:1.80M
Turnover:108.16M
Market Cap:11.60B
PE:158.32
High:60.71
Open:59.90
Low:59.37
Close:59.87
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.92
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.83
PE(LYR):33.33

Loading ...

Biomarin Pharmaceutical - Ascendis to Pay Biomarin 20% US, 18% EU/Br/SK Royalty on Sales Until May 2030 - SEC Filing

THOMSON REUTERS
·
2 hours ago

Biomarin Pharmaceutical - Grants Ascendis License for Transcon Cnp, Navepegritide, Yuviwel - SEC Filing

THOMSON REUTERS
·
2 hours ago

BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products

Reuters
·
2 hours ago

Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026

Reuters
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Biomarin Pharmaceutical Inc. : JP Morgan Raises Target Price to $86 from $80

THOMSON REUTERS
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

BioMarin price target lowered to $97 from $98 at BMO Capital

TIPRANKS
·
Sep 15

BioMarin to discontinue development of Voxzogo for children with Noonan syndrome

TIPRANKS
·
Sep 15

Biomarin Pharmaceutical - Discontinues Development of Voxzogo for Children with Noonan Syndrome on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 15

BioMarin Files Form 3 for Director Robert M. Plenge, Reporting no Beneficial Ownership

Reuters
·
Sep 15

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Biomarin Announces Appointment of Robert Plenge, M.d., Ph.d., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

THOMSON REUTERS
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

BioMarin Pharmaceutical Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

TIPRANKS
·
Sep 09

BioMarin Submits FDA sNDA to Expand Voxzogo Use to Children with Hypochondroplasia

Reuters
·
Sep 09

Biomarin Announces Positive Results of Phase 3 Voxzogo® (Vosoritide) Study in Hypochondroplasia Published in Nejm Evidence

THOMSON REUTERS
·
Sep 09

Clearway Energy Names Steven Ryder CFO Effective Oct. 1

Reuters
·
Sep 09